Concert Pharmaceuticals
2006
FOUNDED
PUBLIC
STATUS
61-70
EMPLOYEES
CNCE
STOCK SYMBOL
$13.50
SHARE PRICE
(As of Friday Closing)
Description
Developer of bio-pharmaceutical drugs designed to address unmet patient needs. The company develops novel, small-molecule drugs, utilizing DCE (deuterated chemical entity) platform, approved drugs, advanced clinical candidates or previously studied compounds that can be improved with deuterium substitution to enhance clinical safety, tolerability and efficacy, targeting central nervous system (CNS) disorders, renal disease, inflammation and cancer.
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Stock Exchange
NAS
Primary Office
- 99 Hayden Avenue
- Suite 500
- Lexington, MA 02421
- United States
+1 (781) 000-0000
Request full access to PitchBook
You’re viewing a free company profile from the PitchBook Platform. To explore Concert Pharmaceuticals’s full profile, request a free trial.
Concert Pharmaceuticals Stock Performance
| 52 wk Range | Market Cap | Prev. Close | EPS | Average Volume | Shares |
|---|---|---|---|---|---|
| $11.30 - $29.05 | $314M | $13.42 | -$1.80 | 225K | 23.4M |
Concert Pharmaceuticals Financials Summary
|
In Thousands,
USD |
TTM
30-Sep-2018
|
FY 2017
31-Dec-2017
|
FY 2016
31-Dec-2016
|
FY 2015
31-Dec-2015
|
|---|---|---|---|---|
| Enterprise Value | 157,308 | 382,015 | 121,210 | 279,299 |
| Revenue | 10,504 | 143,891 | 174 | 66,729 |
| EBITDA | (42,285) | 97,162 | (49,827) | 25,697 |
| Net Income | (41,241) | 95,639 | (50,720) | 24,174 |
| Total Assets | 208,556 | 211,736 | 100,395 | 146,932 |
| Total Debt | 0 | 0 | 0 |
Public Fundamental Data provided by Morningstar, Inc.
disclaimer
Concert Pharmaceuticals Valuation and Funding
| Deal Type | Date | Amount | Post-Val | Valuation/ EBITDA |
Debt | Status |
|---|
This information is reserved for PitchBook Platform users. To explore Concert Pharmaceuticals‘s full profile, request access.
Request full access to PitchBookConcert Pharmaceuticals Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
This information is reserved for PitchBook Platform users. To explore Concert Pharmaceuticals‘s full profile, request access.
Request full access to PitchBookConcert Pharmaceuticals Investors
| Investor Name | Investor Type | Holding | Participating Rounds | Investor Since | Board Seat | Contact Info |
|---|
This information is reserved for PitchBook Platform users. To explore Concert Pharmaceuticals‘s full profile, request access.
Request full access to PitchBookConcert Pharmaceuticals Executive Team (6)
1 Former Executive
You’re viewing 5 of 6 executives. Get the full list »Concert Pharmaceuticals Board Members (10)
| Name | Representing | Role | Since | Contact Info |
|---|---|---|---|---|
| Peter Hutt | Self | Board Member | 000 0000 | |
| Richard Aldrich | Self | Co-Founder & Chairman | 000 0000 | |
| Roger Tung Ph.D | Concert Pharmaceuticals | Co-Founder, Chief Executive Officer, President & Board Member | 000 0000 | |
| Ronald Barrett Ph.D | Self | Board Member | 000 0000 |
6 Former Board Members
You’re viewing 4 of 10 board members. Get the full list »